<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1520">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05141370</url>
  </required_header>
  <id_info>
    <org_study_id>2021-A02331-40</org_study_id>
    <nct_id>NCT05141370</nct_id>
  </id_info>
  <brief_title>Assessment of a Femtosecond Laser to Perform Capsulorhexis During Cataract Surgery</brief_title>
  <official_title>Assessment of a Hand-held Femtosecond Laser to Perform Anterior Capsulorhexis During Cataract Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ilasis Laser</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ilasis Laser</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a Pre-market first-in-man clinical investigation to validate performance of a&#xD;
      hand-held femtosecond laser named CATSYS.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Interventional, prospective, longitudinal (follow-up: 30 ± 10 days), single-arm, single&#xD;
      center, open trial. The &quot;first-in-man&quot; character of this investigation relies on the&#xD;
      ergonomics of CATSYS (handpiece), and not on the laser technique, which is similar to other&#xD;
      FLACS.&#xD;
&#xD;
      The purpose of the clinical investigation is to document the compliance of the&#xD;
      investigational medical device with the general requirements of performance, safety and&#xD;
      clinical benefit, in order to complete existing data and obtaining CE-mark for CATSYS.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2021</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Continuity of the capsulorhexis (success / failure)</measure>
    <time_frame>During surgery</time_frame>
    <description>Success achieved if:&#xD;
the anterior capsule is completely cut (rhexis is free floating or easy to remove)&#xD;
AND there are no peripheric tears that can generate the rupture of the capsule at the end of rhexis removal.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse device effects</measure>
    <time_frame>3 to 5 days after surgery</time_frame>
    <description>Collection of adverse device effects by the investigator on the retina, on the cornea, on the posterior capsula and other adverse device events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>3 to 5 days post-surgery;</time_frame>
    <description>Collection by the investigator of other adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ocular adverse events</measure>
    <time_frame>30 ± 10 days post-surgery.</time_frame>
    <description>Collection by the investigator of ocular adverse events</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">78</enrollment>
  <condition>Cataract Surgery</condition>
  <arm_group>
    <arm_group_label>hand-held femtosecond laser</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Anterior capsulorhexis will be performed with a hand-held femtosecond laser named CATSYS.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>cataract surgery with CATSYS</intervention_name>
    <description>patient diagnosed with cataract requiring surgery will have an anterior capsulorhexis with CATSYS</description>
    <arm_group_label>hand-held femtosecond laser</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosed with cataract requiring surgery according to current guidelines;&#xD;
&#xD;
          -  Eligible to lens removal by phacoemulsification and replacement by a prosthetic lens&#xD;
             under local anesthesia;&#xD;
&#xD;
          -  Who have been informed and gave informed consent to participate in the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Eye with an anterior chamber depth &lt; 2.5 mm or &gt; 3.8 mm;&#xD;
&#xD;
          -  Corneal disease or pathology that precludes applanation of the cornea or transmission&#xD;
             of laser wavelength or distortion of laser light;&#xD;
&#xD;
          -  Eye with a poorly dilating pupil or other defect of the pupil that prevents the iris&#xD;
             from adequate retraction peripherally;&#xD;
&#xD;
          -  Patient with residual, recurrent, active ocular or eyelid disease, including any&#xD;
             corneal abnormality (for example, recurrent corneal erosion, severe basement membrane&#xD;
             disease) in either eye;&#xD;
&#xD;
          -  History of steroid-responsive rise in IOP, glaucoma, or preoperative IOP&gt;21 mm Hg in&#xD;
             either eye;&#xD;
&#xD;
          -  Lens/zonular instability such as, but not restricted to, Marfan's Syndrome,&#xD;
             pseudoexfoliation syndrome, etc;&#xD;
&#xD;
          -  Previous intraocular or corneal surgery of any kind, including any type of surgery for&#xD;
             either refractive or therapeutic purposes in either eye;&#xD;
&#xD;
          -  Any recent penetrating incision of the eyeball;&#xD;
&#xD;
          -  Tilt of lens &gt; 7;&#xD;
&#xD;
          -  Presence of any obstacle that may interfere with the stabilization of the device on&#xD;
             the limbus: pterygium, limbic tumor, etc;&#xD;
&#xD;
          -  Pregnant or lactating woman;&#xD;
&#xD;
          -  Patient with any contra-indication to neosynephrine, tropicamide and oxybuprocaïne;&#xD;
&#xD;
          -  Patient presenting any contraindications to cataract surgery under local anesthesia&#xD;
             (ex: allergy to anesthetic drops; neurodegenerative disease; schizophrenia; severe&#xD;
             anxiety; etc.);&#xD;
&#xD;
          -  Patient who participates to another clinical trial (except observational studies), or&#xD;
             in the exclusion period of another clinical trial;&#xD;
&#xD;
          -  Patient under guardianship, trusteeship or deprived of liberty;&#xD;
&#xD;
          -  Patient not affiliated to the French social security system;&#xD;
&#xD;
          -  Patient unable to participate in the study for psychiatric, cognitive or linguistic&#xD;
             reasons.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>DELOISON Florent</last_name>
    <phone>+33 601 911 003</phone>
    <email>florent.deloison@ilasis.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institut Opthalmologique Sourdille Atlantique</name>
      <address>
        <city>Saint-Herblain</city>
        <zip>44800</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>François LIGNEREUX, MD</last_name>
      <phone>02 40 95 80 89</phone>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 19, 2021</study_first_submitted>
  <study_first_submitted_qc>November 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 2, 2021</study_first_posted>
  <last_update_submitted>November 19, 2021</last_update_submitted>
  <last_update_submitted_qc>November 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

